Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA
NTLA-5001 is Intellia Therapeutics (NTLA) first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. It is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms’ Tumor (WT1) antigen for the treatment of all genetic subtypes . . .
This content is for paid subscribers.
Today’s Highlights September 16, 2021